John F. Cryan is Professor & Chair, Dept. of Anatomy & Neuroscience, University College Cork and serves on the University’s Governing Body.  He is also a Principal Investigator in the APC Microbiome Institute. He received a B.Sc. (Hons) and PhD from the National University of Ireland, Galway, Ireland. He was a visiting fellow at the Dept Psychiatry, University of Melbourne, Australia, which was followed by postdoctoral fellowships at the University of Pennsylvania, Philadelphia, USA and The Scripps Research Institute, La Jolla, California. He spent four years at the Novartis Institutes for BioMedical Research in Basel Switzerland, as a LabHead, Behavioural Pharmacology prior to joining UCC in 2005. Prof. Cryan’s current research is focused on understanding the interaction between brain, gut & microbiome and how it applies to stress, psychiatric and immune-related disorders at key time-windows across the lifespan. Prof. Cryan has a H-index of 69 having published over 300 peer-reviewed articles and book chapters. He is a Senior Editor of Neuropharmacology and of Nutritional Neuroscience and an Editor of British Journal of Pharmacology. He is on the editorial board of a further 15 journals. He has edited three books including “Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease” (Springer Press, 2014). He has received many awards including UCC Researcher of the Year in 2012; the University of Utrecht Award for Excellence in Pharmaceutical Research in 2013 and being named on the Thomson Reuters Highly Cited Researcher list in 2014. He was a TEDMED speaker in Washington in 2014 and spoke at WIRED Health in London in 2015. He was named President-elect of the European Behavioural Pharmacology Society in 2015.

Daniel W. Armstrong is the Robert A. Welch Professor of Chemistry at the University of Texas at Arlington.   He received his B.S. (1972) from Washington and Lee University and his M.S. (1974) and Ph.D. degrees (1977) from Texas A&M University.  He has over 600 publications including 29 book chapters, one book (“Use of Ordered Media in Chemical Separations”) and 30 patents. He has given over 550 invited seminars and colloquia worldwide.  He is considered the “Father” of pseudophase (micelle and cyclodextrin-based) separations.  He elucidated the first chiral recognition mechanism for cyclodextrins.  He also first developed macrocyclic antibiotics as chiral selectors.  He is one of the world’s leading authorities on the theory, mechanism and use of enantioselective molecular interactions.  Over 30 different LC and GC columns originally developed in his laboratories have been commercialized and/or copied worldwide.  His work and columns were in part responsible for the chromatography and electrophoresis – lead revolution in chiral separations over the last two decades. This work provided the impetus for the FDA’s regulatory changes regarding chiral drug development in 1992. He also developed the most comprehensive solvation and characterization models for room temperature ionic liquids (RTILs) and pioneered their use in analytical chemistry (separations and mass spectrometry).  More recently, he has developed rapid, high efficiency, microfluidic methods for analyzing microorganisms and colloidal particles.

Professor Armstrong has received the Eastern Analytical Award for Chromatography (1990), Great Britain’s Martin Medal (1991) (named for Nobel laureate A.P.J. Martin), and the Isco Award for contributions to instrumentation for biochemical separations(1991), the Presidential Award for Research and Creativity (1993), the ACS Midwest Award in Chemistry (1993), the Perkin Elmer Award for Capillary Electrophoresis (1994),  The R&D 100 Award for Inventions leading to a better world (1995), and was named a Fellow of the American Association of Pharmaceutical Scientists (1995).  In 1996 he was given the Benedetti-Pichler Award in microchemistry; in 1997, the Karen Morehouse Award, in 1998 the ACS Helen M. Free Award, and in 1999 the ACS Award in Chromatography, in 1999 the Distinguish Scholar Award from Hope College/Park Davis, and in 2001 the Chicago Area Chromatography Discussion Group (CCDG) Merit Award.  He was awarded the Weber Medal, and was made an honorary member of the Slovacae Pharmaceutical Society, for his contributions to the Pharmaceutical Sciences (2001).  He received the Spencer Award for Agriculture and Food Chemistry in 2002, the Chirality Medal, 2003 and the Zuffa medal for Pharmaceutical Chemistry, 2004.  He was the 2005 Dal Nogre Award winner presented at the Pittsburgh Conference and was awarded the 2007 Medal of the Slovak Medical Society. Named a Fellow of the Royal Society of Chemistry in 2009. Named American Chemical Society Fellow, 2013.  UTA Distinguished Record of Research or Creative Activity 2012.  ACS Award for Separation Science & Technology, 2014. 2014 M.J.E. Golay Award.  UT Arlington Distinguished Scholars Award 2014. He was elected to the National Academy of Inventors in 2014. He is the Separations Associate Editor for Analytical Chemistry and was the Editor of the international journal Chirality, a Section Editor for Amino Acids, and a member of the Editorial Board of over 20 other journals. He is a member of the American Chemical Society, American Association for the Advancement of Science, Smithsonian Associate and Sigma XI.  His current research involves chiral recognition, specific separation and detection of enantiomers, cyclodextrin chemistry, investigation of biologically active molecules, macrocyclic antibiotics, and high efficiency microbial analysis, and use of room temperature ionic liquids in chemical analysis and separations. He also has interests in a variety of other areas from oceanography to gemstone analysis. He originated and broadcast the NPR (National Public Radio) show, “We’re Science” that was broadcast on ~140 stations and the Armed Forces Network.

The bio-tech company, Advanced Separation Technologies, Inc. (a.k.a. Astec), was jointly formed by Professor Armstrong and his colleagues in 1983, and purchased by Aldrich/Sigma/Supelco, which is the largest specialty chemical company in the world. He started a new company (AZYP, LLC) which specializes in new chiral and HILIC LC columns and cyclofructan development. He also was on the Scientific Advisory Board of three corporations and one university.

Paul Haddad has obtained the degrees of BSc, PhD and DSc from the University of New South Wales.  His academic career has been spent at the Australian National University, the University of New South Wales, and since 1992 at the University of Tasmania where he is currently an Emeritus Distinguished Professor of Chemistry. He also held a five-year appointment as an Australian Research Council Federation Fellow.  He was Foundation Director of the Australian Centre for Research on Separation Science and Director of the Pfizer Analytical Research Centre.  He has a long-standing research interest in analytical separations of inorganic species and has more than 500 publications in this general field.  He has also presented in excess of 500 papers at local and international scientific meetings.  He is a Fellow of the Australian Academy of Science and the Australian Academy of Technological Sciences and Engineering.

He is an editor of Journal of Chromatography A (since 2005), a contributing editor for Trends in Analytical Chemistry (since 2000), and was an editor of Analytica Chimica Acta for 6 yearsHe is currently a member of the editorial boards of 10 other journals of analytical chemistry or separation science.

He is the recipient of a number of national and international awards, including the American Chemical Society Chromatography Award, AJP Martin Gold Medal awarded by the Chromatographic Society, the Marcel Golay Award, the Royal Society of Chemistry Analytical Separation Methods Award, the Royal Australian Chemical Institute HG Smith and Analytical Division medals, and the inaugural University of Tasmania Vice-Chancellor’s Medal for Research Excellence.

Professor Pauline M. Rudd BSc, LRIC, MA (Oxon), PhD is the Adjunct Professor of Glycobiology at University College, Dublin. She heads the GlycoSciences Research Group at the National Institute for BioProcessing Research and Training in Ireland (NIBRT) where she is also a consultant. She is also a Visiting Investigator at the Bioprocessing Technology Institute (BTI), in A-Star, Singapore.
Pauline Rudd has many links with academic groups, regulators and pharmaceutical companies across the world because GlycoScience is a major area of specialised expertise required to probe the pathways in diseases and to ensure the safety and efficacy of biotherapeutic drugs, such as monoclonal antibodies for cancer and autoimmune disorders.

Professor Rudd obtained a BSc in Chemistry at the University of London and a PhD in Glycobiology at the Open University, UK. She was a Founding Scientist of Wessex Biochemicals (later Sigma London), Visiting Research Associate at The Scripps Research Institute, CA, Visiting Professor of Biochemistry at Shanghai Medical University PRC, Visiting Scientist at Ben Gurion University of the Negev, Israel and Erskine Visiting Fellow, Canterbury University, Christchurch, New Zealand. She is a Fellow of the Royal Society of Medicine, London and a Visiting Professor at St. George’s Hospital, London and an Adjunct Professor at North Eastern University, Boston, NUI Galway and Trinity College Dublin.  


She has more than 300 scientific publications and has given over 350 lectures and seminars at international meetings. Her research has focussed on developing novel technologies and bioinformatics programmes to probe disease related glycosylation changes and systems biology, particularly in cancer and immunology. She has held seven FP7 grants with colleagues from many EU countries. In 2010 she was awarded the James Gregory Medal and an Agilent Thought Leader award and in 2012 she received a Waters Global Innovation award. In 2014 she was awarded an Honorary Doctorate at Sahlgrenska Academy in Gothenburg University, Sweden. Before moving her group to Dublin in 2006,

 

Professor Rudd was a member of the Oxford Glycobiology Institute for 25 years. When she left she was a Senior Research Fellow and a University Reader in Glycobiology.

Jean-Luc Veuthey is a full professor at the School of Pharmaceutical Sciences, University of Geneva, Switzerland. His research domain is dedicated to the development of analytical techniques in pharmaceutical sciences for the analysis of drugs and drugs abuse in different biological matrices. He is also interested with the doping control analysis and is member of the UEFA Anti-Doping Panel since 2005.

Jean-Luc Veuthey is author of more than 300 scientific publications and book chapters. He is also active in different both national and international scientific committees.

Mario Thevis (*1973) graduated in organic chemistry and sports sciences in 1998. He earned his PhD in Biochemistry in 2001 and did post-doctoral research at the Department of Chemistry and Biochemistry of the University of California Los Angeles (UCLA) in 2002. After being a senior researcher from 2003 to 2005 he was appointed as Professor for Preventive Doping Research at the German Sport University Cologne in 2006. Mario Thevis further qualified as Forensic Chemist, acts as director of the European Monitoring Center for Emerging Doping Agents (EuMoCEDA), and is Editor-in-Chief of Drug Testing & Analysis. Since 2014, Professor Thevis is also vice president for research at the German Sport University Cologne.

Wolfgang Lindner studied chemistry at the KFU-Graz, Austria, where he worked for over 20 years at the Institute of Pharmaceutical Chemistry . In 1996 he was appointed a Chair of Analytical Chemistry at the University of Vienna, Austria, became Emeritus in 2012 but is still active. Throughout his career he got strongly influenced by life sciences themes spanning from pharmaceutical analysis, metabolomics, proteomics, etc. and separation science methodologies as of HPLC, SFC, GC, CE/CEC and LC-MS. In this context particular interest developed towards non-covalent interactions and molecular recognition phenomena as molecular selectivity criteria with focus on stereochemistry leading to the development of novel synthetic selectors useful also for enantioselective separation techniques. Working on the interface of organic, analytical and biological chemistry characterizes best his scientific credo expressed by a rich portfolio of publications and patents.